I am Assistant Professor in Pediatrics and Head of Pediatric Gastroenterology, Hepatology and Nutrition Unit, working at the 3rd Pediatric Department of the University of Athens “ATTIKON” University Hospital of Athens.
I am full member in ESPGHAN since 2015 (trainee since 2009).
I have successfully completed my PhD thesis in University of Athens Medical School (May 2009).
My teaching experience is: i) training of medical students in Pediatrics with lectures and teaching in the wards, ii) training of pediatric residents and continuing education of pediatricians with lectures and seminars.
I have 29 publications in medical journals and 32 abstracts publications, 106 presentations in medical congresses and 52 lectures as invited speaker.
Participation in the following research projects:
1. TEEN-AGE project (Tutorial European Electronic e-learning Network on Acute Gastroenteritis) performed by ESPGHAN (European Society Pediatric Gastroenterology, Hepatology and Nutrition)
2. EU-funded project Stance4Health (Smart Technologies for Personalized Nutrition and Consumer Engagement)
3. OVARTIS CTDT600A2306 study: A Randomized, Double-Blind, 104-Weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents with Compensated HBeAG-Positive and Negative Chronic Hepatitis B Virus Infection (2014-2018)
4. GILEAD GS-EU-174-1403 study: Evaluation of bone and renal safety of Tenofovir. Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicity in Chronic Hepatitis B (CHB)-infected adolescents aged 12 to <18 years in Europe (2015-2019)
5. UR-CARE United Registries for Clinical Assessment and Research Cohort performed by ECCO (European Crohn’s & Colitis Organisation)
6. TAKEDA MLN0002-3024 / MLN0002-3025: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis / Crohn Disease Who Achieved Clinical Response Following Open–Label Vedolizumab Intravenous Therapy